Article info

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Authors

  • Hui Yu State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Ping Chen State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Liangping Xia State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Sha Fu Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Pathology Department, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Chen Chen State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China PubMed articlesGoogle scholar articles
  • Xuanye Zhang State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Lina He State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Bei Zhang State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Yixin Zhou State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Shaodong Hong State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Bei Zhang; zhangbei{at}sysucc.org.cn; Dr Yixin Zhou; zhouyx{at}sysucc.org.cn; Dr Shaodong Hong; hongshd{at}sysucc.org.cn
View Full Text

Citation

Yu H, Chen P, Xia L, et al
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Publication history

  • Accepted October 4, 2021
  • First published November 8, 2021.
Online issue publication 
November 08, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.